Patients with SF3B1-mutated UM show early- and late-onset metastatic disease (defined as before or after a follow-up time of 60 months), for which, currently, no biomarkers exist, and for which we identified several promising candidates with potential distinguishing characteristics when implemented within an expression-based classifier. Here, SF3B1 is linked to metastatic neoplasm.